Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources

Karen K. Ballen; Steven Joffe; Ruta Brazauskas; Zhiwei Wang; Mahmoud D. Aljurf; Görgün Akpek; Christopher Dandoy; Haydar A. Frangoul; César O. Freytes; Nandita Khera; Hillard M. Lazarus; Charles F. LeMaistre; Paulette Mehta; Susan K. Parsons; David Szwajcer; Celalettin Ustun; William A. Wood; Navneet S. Majhail

doi:10.1016/j.bbmt.2014.07.021

Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources

Karen K. Ballen, Steven Joffe, Ruta Brazauskas, Zhiwei Wang, Mahmoud D. Aljurf, Görgün Akpek, Christopher Dandoy, Haydar A. Frangoul, César O. Freytes, Nandita Khera, Hillard M. Lazarus, Charles F. LeMaistre, Paulette Mehta, Susan K. Parsons, David Szwajcer, Celalettin Ustun, William A. Wood, Navneet S. Majhail

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.

Original language	English (US)
Pages (from-to)	1819-1827
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.bbmt.2014.07.021
State	Published - Nov 1 2014

Bibliographical note

Funding Information:
Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute , the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015 C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB ; Allos, Inc. ; Amgen, Inc. ; Anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US, Inc. ; Be the Match Foundation ; Biogen Idec BioMarin Pharmaceutical, Inc. ; Biovitrum AB ; BloodCenter of Wisconsin ; Blue Cross and Blue Shield Association ; Bone Marrow Foundation ; The Bailey Family Foundation ; Terumo BCT Celgene ; CellGenix Children's Leukemia Research Association ; ClinImmune Labs ; CTI Clinical Trial and Consulting Services ; Eisai, Inc. ; Genentech, Inc. ; Genzyme Corporation ; Histogenetics, Inc. ; HKS Medical Information Systems ; Hospira, Inc. ; Kirin Brewery Co., Ltd. ; The Leukemia & Lymphoma Society ; Merck & Company ; The Medical College of Wisconsin ; Millennium Pharmaceuticals, Inc. ; Miller Pharmacal Group ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Nature Publishing Group ; Novartis Oncology ; Oncology Nursing Society ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; Pall Life Sciences ; Pfizer Inc ; Schering Corporation ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, Inc. ; StemSoft Software, Inc. ; Sysmex America, Inc. ; Texas Instruments Inc. ; Vidacare Corporation ; ViraCor Laboratories ; ViroPharma, Inc. ; and WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the; Navy, the Department of Defense, or any other agency of the U.S. Government.

Publisher Copyright:
© 2014 American Society for Blood and Marrow Transplantation.

Keywords

Hematopoietic cell transplantation
Length of stay
Leukemia
Resource utilization
Umbilical cord blood

Publisher link

10.1016/j.bbmt.2014.07.021

Find It

Find It at U of M Libraries

Cite this

Ballen, K. K., Joffe, S., Brazauskas, R., Wang, Z., Aljurf, M. D., Akpek, G., Dandoy, C., Frangoul, H. A., Freytes, C. O., Khera, N., Lazarus, H. M., LeMaistre, C. F., Mehta, P., Parsons, S. K., Szwajcer, D., Ustun, C., Wood, W. A., & Majhail, N. S. (2014). Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 20(11), 1819-1827. https://doi.org/10.1016/j.bbmt.2014.07.021

Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission : Comparison among Alternative Graft Sources. / Ballen, Karen K.; Joffe, Steven; Brazauskas, Ruta et al.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 11, 01.11.2014, p. 1819-1827.

Research output: Contribution to journal › Article › peer-review

Ballen, KK, Joffe, S, Brazauskas, R, Wang, Z, Aljurf, MD, Akpek, G, Dandoy, C, Frangoul, HA, Freytes, CO, Khera, N, Lazarus, HM, LeMaistre, CF, Mehta, P, Parsons, SK, Szwajcer, D, Ustun, C, Wood, WA & Majhail, NS 2014, 'Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources', Biology of Blood and Marrow Transplantation, vol. 20, no. 11, pp. 1819-1827. https://doi.org/10.1016/j.bbmt.2014.07.021

@article{1d100a3b1a4141fcb1ba33b6fcf9741f,

title = "Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources",

abstract = "Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.",

keywords = "Hematopoietic cell transplantation, Length of stay, Leukemia, Resource utilization, Umbilical cord blood",

author = "Ballen, {Karen K.} and Steven Joffe and Ruta Brazauskas and Zhiwei Wang and Aljurf, {Mahmoud D.} and G{\"o}rg{\"u}n Akpek and Christopher Dandoy and Frangoul, {Haydar A.} and Freytes, {C{\'e}sar O.} and Nandita Khera and Lazarus, {Hillard M.} and LeMaistre, {Charles F.} and Paulette Mehta and Parsons, {Susan K.} and David Szwajcer and Celalettin Ustun and Wood, {William A.} and Majhail, {Navneet S.}",

note = "Funding Information: Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute , the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015 C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB ; Allos, Inc. ; Amgen, Inc. ; Anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US, Inc. ; Be the Match Foundation ; Biogen Idec BioMarin Pharmaceutical, Inc. ; Biovitrum AB ; BloodCenter of Wisconsin ; Blue Cross and Blue Shield Association ; Bone Marrow Foundation ; The Bailey Family Foundation ; Terumo BCT Celgene ; CellGenix Children's Leukemia Research Association ; ClinImmune Labs ; CTI Clinical Trial and Consulting Services ; Eisai, Inc. ; Genentech, Inc. ; Genzyme Corporation ; Histogenetics, Inc. ; HKS Medical Information Systems ; Hospira, Inc. ; Kirin Brewery Co., Ltd. ; The Leukemia & Lymphoma Society ; Merck & Company ; The Medical College of Wisconsin ; Millennium Pharmaceuticals, Inc. ; Miller Pharmacal Group ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Nature Publishing Group ; Novartis Oncology ; Oncology Nursing Society ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; Pall Life Sciences ; Pfizer Inc ; Schering Corporation ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, Inc. ; StemSoft Software, Inc. ; Sysmex America, Inc. ; Texas Instruments Inc. ; Vidacare Corporation ; ViraCor Laboratories ; ViroPharma, Inc. ; and WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the; Navy, the Department of Defense, or any other agency of the U.S. Government. Publisher Copyright: {\textcopyright} 2014 American Society for Blood and Marrow Transplantation.",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/j.bbmt.2014.07.021",

language = "English (US)",

volume = "20",

pages = "1819--1827",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission

T2 - Comparison among Alternative Graft Sources

AU - Ballen, Karen K.

AU - Joffe, Steven

AU - Brazauskas, Ruta

AU - Wang, Zhiwei

AU - Aljurf, Mahmoud D.

AU - Akpek, Görgün

AU - Dandoy, Christopher

AU - Frangoul, Haydar A.

AU - Freytes, César O.

AU - Khera, Nandita

AU - Lazarus, Hillard M.

AU - LeMaistre, Charles F.

AU - Mehta, Paulette

AU - Parsons, Susan K.

AU - Szwajcer, David

AU - Ustun, Celalettin

AU - Wood, William A.

AU - Majhail, Navneet S.

N1 - Funding Information: Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute , the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015 C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB ; Allos, Inc. ; Amgen, Inc. ; Anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US, Inc. ; Be the Match Foundation ; Biogen Idec BioMarin Pharmaceutical, Inc. ; Biovitrum AB ; BloodCenter of Wisconsin ; Blue Cross and Blue Shield Association ; Bone Marrow Foundation ; The Bailey Family Foundation ; Terumo BCT Celgene ; CellGenix Children's Leukemia Research Association ; ClinImmune Labs ; CTI Clinical Trial and Consulting Services ; Eisai, Inc. ; Genentech, Inc. ; Genzyme Corporation ; Histogenetics, Inc. ; HKS Medical Information Systems ; Hospira, Inc. ; Kirin Brewery Co., Ltd. ; The Leukemia & Lymphoma Society ; Merck & Company ; The Medical College of Wisconsin ; Millennium Pharmaceuticals, Inc. ; Miller Pharmacal Group ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Nature Publishing Group ; Novartis Oncology ; Oncology Nursing Society ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; Pall Life Sciences ; Pfizer Inc ; Schering Corporation ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, Inc. ; StemSoft Software, Inc. ; Sysmex America, Inc. ; Texas Instruments Inc. ; Vidacare Corporation ; ViraCor Laboratories ; ViroPharma, Inc. ; and WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the; Navy, the Department of Defense, or any other agency of the U.S. Government. Publisher Copyright: © 2014 American Society for Blood and Marrow Transplantation.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.

AB - Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.

KW - Hematopoietic cell transplantation

KW - Length of stay

KW - Leukemia

KW - Resource utilization

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=84908043609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908043609&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.07.021

DO - 10.1016/j.bbmt.2014.07.021

M3 - Article

C2 - 25064747

AN - SCOPUS:84908043609

SN - 1083-8791

VL - 20

SP - 1819

EP - 1827

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 11

ER -

Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this